PSTX · Poseida Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71.75M | $25.97M | $28.14M | - | $9.35M | $20.01M | $10.34M | - | $116.31M | $2.70M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $41.91M | $45.55M | $42.92M | - | $37.48M | $39.19M | $38.05M | - | $35.14M | $35.01M |
| SG&A | $10.09M | $12.18M | $9.80M | - | $8.09M | $8.68M | $11.81M | - | $9.39M | $9.24M |
| Total Operating Expenses | $52.01M | $57.73M | $52.72M | - | $45.57M | $47.87M | $49.86M | - | $44.53M | $44.24M |
| D&A | $1.30M | $1.30M | $1.38M | - | $1.40M | $1.40M | $1.32M | - | $1.40M | $1.30M |
| Operating Income | $19.74M | ($31.76M) | ($24.58M) | - | ($36.22M) | ($27.86M) | ($39.52M) | - | $71.78M | ($41.55M) |
| Interest Expense | $2.29M | $2.26M | $2.25M | - | $2.24M | $2.14M | $2.03M | - | $1.77M | $1.54M |
| Income Tax | $43.0K | - | - | - | $107.0K | - | - | - | $252.0K | - |
| Net Income | $20.23M | ($31.37M) | ($24.27M) | - | ($31.78M) | ($27.46M) | ($38.85M) | - | $70.41M | ($43.04M) |
| EPS - Basic | $0.21 | ($0.32) | ($0.25) | - | ($0.35) | ($0.32) | ($0.45) | - | $0.92 | ($0.74) |
| EPS - Diluted | $0.21 | ($0.32) | ($0.25) | - | ($0.35) | ($0.32) | ($0.45) | - | $0.92 | ($0.74) |
Balance Sheet
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $49.34M | $30.55M | $53.30M | $44.47M | $25.50M | $49.91M | $40.14M | $81.38M | $164.81M | $62.96M |
| Accounts Receivable | $14.75M | $12.43M | $12.03M | $9.01M | $8.67M | $11.91M | $8.44M | $9.09M | $38.47M | $232.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $5.20M | $2.99M | $2.70M | $3.27M | $2.54M | $2.10M | $3.20M | $2.23M | $3.43M | $3.66M |
| Current Assets | $250.70M | $254.34M | $216.73M | $226.47M | $252.66M | $230.19M | $260.70M | $298.56M | $325.13M | $148.12M |
| Total Assets | $293.58M | $298.69M | $262.58M | $273.88M | $302.25M | $281.21M | $313.62M | $351.84M | $380.48M | $205.46M |
| Current Liabilities | $78.27M | $102.43M | $84.76M | $71.32M | $76.97M | $49.89M | $48.69M | $53.88M | $48.97M | $40.09M |
| Long-term Debt | $58.91M | $58.80M | $58.69M | $58.59M | $58.49M | $58.40M | $58.32M | $58.25M | $58.16M | $58.06M |
| Total Liabilities | $206.37M | $237.87M | $177.99M | $170.18M | $178.59M | $145.91M | $156.06M | $164.24M | $164.17M | $139.66M |
| Stockholders' Equity | $87.21M | $60.82M | $84.59M | $103.70M | $123.66M | $135.30M | $157.56M | $187.59M | $216.31M | $65.80M |
| Retained Earnings | ($629.70M) | ($649.94M) | ($618.57M) | ($594.29M) | ($568.94M) | ($537.16M) | ($509.71M) | ($470.86M) | ($437.54M) | ($507.95M) |
Cash Flow
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($15.13M) | - | - | - | ($38.01M) | - | - | - |
| Investing Cash Flow | - | - | $24.00M | - | - | - | ($4.42M) | - | - | - |
| Financing Cash Flow | - | - | ($43.0K) | - | - | - | $1.19M | - | - | - |
| CapEx | - | - | $130.0K | - | - | - | $784.0K | - | - | - |
| Free Cash Flow | - | - | ($15.27M) | - | - | - | ($38.79M) | - | - | - |
Ratios
| Metric | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | 27.5% | -122.3% | -87.3% | - | -387.3% | -139.2% | -382.1% | - | 61.7% | -1538.7% |
| EBITDA margin | 29.3% | -117.3% | -82.4% | - | -372.3% | -132.2% | -369.3% | - | 62.9% | -1490.6% |
| Net margin | 28.2% | -120.8% | -86.3% | - | -339.8% | -137.2% | -375.6% | - | 60.5% | -1593.9% |
| Free cash flow margin | - | - | -54.2% | - | - | - | -375.0% | - | - | - |
| FCF / Net income | - | - | 0.63 | - | - | - | 1.00 | - | - | - |
| R&D / Revenue | 58.4% | 175.4% | 152.5% | - | 400.8% | 195.8% | 367.9% | - | 30.2% | 1296.6% |
| SG&A / Revenue | 14.1% | 46.9% | 34.8% | - | 86.5% | 43.4% | 114.2% | - | 8.1% | 342.1% |
| Effective tax rate | 0.2% | - | - | - | - | - | - | - | 0.4% | - |
| Return on assets | 6.9% | -10.5% | -9.2% | - | -10.5% | -9.8% | -12.4% | - | 18.5% | -20.9% |
| Return on equity | 23.2% | -51.6% | -28.7% | - | -25.7% | -20.3% | -24.7% | - | 32.5% | -65.4% |
| Return on invested capital | 13.5% | - | - | - | -15.7% | - | - | - | 26.1% | - |
| Liquidity | ||||||||||
| Current ratio | 3.20 | 2.48 | 2.56 | 3.18 | 3.28 | 4.61 | 5.35 | 5.54 | 6.64 | 3.69 |
| Quick ratio | 3.20 | 2.48 | 2.56 | 3.18 | 3.28 | 4.61 | 5.35 | 5.54 | 6.64 | 3.69 |
| Cash ratio | 0.63 | 0.30 | 0.63 | 0.62 | 0.33 | 1.00 | 0.82 | 1.51 | 3.37 | 1.57 |
| Leverage | ||||||||||
| Debt / Equity | 0.68 | 0.97 | 0.69 | 0.56 | 0.47 | 0.43 | 0.37 | 0.31 | 0.27 | 0.88 |
| Debt / Assets | 0.20 | 0.20 | 0.22 | 0.21 | 0.19 | 0.21 | 0.19 | 0.17 | 0.15 | 0.28 |
| Debt / EBITDA | 2.80 | - | - | - | - | - | - | - | 0.79 | - |
| Interest coverage | 8.6x | -14.1x | -10.9x | - | -16.2x | -13.0x | -19.5x | - | 40.4x | -26.9x |
| Equity multiplier | 3.37 | 4.91 | 3.10 | 2.64 | 2.44 | 2.08 | 1.99 | 1.88 | 1.76 | 3.12 |
| Liabilities / Assets | 0.70 | 0.80 | 0.68 | 0.62 | 0.59 | 0.52 | 0.50 | 0.47 | 0.43 | 0.68 |
| Efficiency | ||||||||||
| Asset turnover | 0.24 | 0.09 | 0.11 | - | 0.03 | 0.07 | 0.03 | - | 0.31 | 0.01 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 75d | 175d | 156d | - | 338d | 217d | 298d | - | 121d | 31d |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 667.2% | 29.8% | 172.1% | - | -92.0% | 641.2% | 620.8% | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | -14.0% | 37.8% | - | - | 33.0% | 30.6% | - | - | 7.4% |
| Net income growth (YoY) | - | -14.3% | 37.5% | - | - | 36.2% | 33.1% | - | - | 5.8% |
| EPS growth (YoY) | - | 0.0% | 44.4% | - | - | 56.8% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | 60.6% | - | - | - | 25.5% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -29.5% | -55.1% | -46.3% | -44.7% | -42.8% | 105.6% | 51.9% | 20.1% | 44.1% | -64.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$64.70M totalCollaboration Revenue$64.70M · 100.0%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Poseida Therapeutics against the 5 most active filers in the same SIC group.